XML 30 R14.htm IDEA: XBRL DOCUMENT v3.20.2
Goodwill and Intangible Assets
 12 Months Ended
Oct. 02, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets GOODWILL AND INTANGIBLE ASSETS
 
The following table reflects the activity of goodwill by reportable operating segment:
(In millions)Oncology
Systems		Proton SolutionsOtherTotal
Balance at September 28, 2018$242.1 $51.5 $— $293.6 
Business combinations208.0 — 164.3 372.3 
Impairment charges— (50.5)— (50.5)
Measurement period adjustment to a business combination prior year(2.2)— — (2.2)
Foreign currency translation adjustments— (1.0)— (1.0)
Balance at September 27, 2019447.9 — 164.3 612.2 
Business combinations15.7 — — 15.7 
Measurement period adjustment to a business combination in prior year(5.6)— 3.8 (1.8)
Foreign currency translation adjustments(3.3)— 1.1 (2.2)
Balance at October 2, 2020$454.7 $— $169.2 $623.9 
See Note 2, "Business Combinations," for more information on the business combinations and measurement period adjustments to business combinations in prior years.

Due to certain indicators identified related to the Company's Interventional Solutions reporting unit in the second quarter of fiscal year 2020, including a significant decrease in near term revenue projections due to COVID-19, Management identified a triggering event and performed an interim impairment test on the $164.3 million of goodwill in its Interventional Solutions reporting unit, within the Other reportable operating segment. The fair value of the Interventional Solutions’ reporting unit was in excess of its carrying value by approximately $20 million, or 7%. Management believes the methodology and significant assumptions, revenue growth rates, operating margins, and weighted-average cost of capital used to calculate the fair value to be reasonable as of April 3, 2020. Management also performed the annual goodwill impairment assessment on its Interventional Solutions reporting unit, within the Other reportable operating segment, during the fourth quarter of fiscal year 2020. Management determined that the fair value of the Interventional Solutions’ reporting unit was in excess of its carrying value by
approximately $72 million, or 27%. Management believes the methodology and assumptions used to calculate the fair value to be reasonable as of July 3, 2020. However, the Interventional Solutions reporting unit could be at risk for a future goodwill impairment if there are adjustments to certain assumptions used in the fair value calculation, including revenue growth rates, operating margins, and weighted-average cost of capital and/or working capital requirements. Given the uncertain impact of COVID-19 and/or other market factors on the Company's business, its cash flow projections for this business could decrease in the future, which could lead to an impairment of goodwill.
Determining the fair value of a reporting unit involves the use of significant estimates and assumptions. These estimates and assumptions include revenue growth rates, operating margins, working capital requirements, weighted-average cost of capital, future economic and market conditions, estimation of the long-term rate of growth for the Company's business and determination of appropriate market comparables. Management bases the fair value estimates on assumptions it believes to be reasonable but that are inherently uncertain. Actual future results related to assumed variables could differ from these estimates. In addition, management makes certain judgments and assumptions in allocating assets and liabilities to determine the carrying values for each reporting unit.
The following table reflects the gross carrying amount and accumulated amortization of the Company’s intangible assets, net:
October 2, 2020September 27, 2019
(In millions)Gross Carrying AmountAccumulated AmortizationNet Carrying AmountGross Carrying AmountAccumulated AmortizationNet Carrying Amount
Technologies and patents$228.0 $(110.9)$117.1 $226.4 $(85.9)$140.5 
Customer contracts, supplier relationships and partner relationships128.9 (34.7)94.2 121.1 (25.7)95.4 
Trade names53.0 (7.0)46.0 55.1 (3.0)52.1 
Other7.8 (6.1)1.7 6.1 (6.1)— 
Total intangible with finite lives417.7 (158.7)259.0 408.7 (120.7)288.0 
In-process R&D with indefinite lives12.3 — 12.3 12.7 — 12.7 
Total intangible assets$430.0 $(158.7)$271.3 $421.4 $(120.7)$300.7 
Amortization expense for intangible assets was $38.2 million, $27.3 million and $20.6 million for fiscal years 2020, 2019 and 2018, respectively.
As of October 2, 2020, the Company estimates that its remaining amortization expense for intangible assets with finite lives will be as follows (in millions):
Fiscal YearsTotal
2021$37.3 
202235.9 
202334.7 
202427.0 
202522.5 
Thereafter101.6 
Total remaining amortization$259.0